Last updated: February 13, 2026
What Is the Current Market Status of NDC 72603-0275?
The drug identified by NDC 72603-0275 is Volanesorsen, marketed as Waylivra. Approved by the U.S. Food and Drug Administration (FDA) in August 2019, this antisense oligonucleotide targets apolipoprotein C-III (apoC-III), used primarily for familial chylomicronemia syndrome (FCS). Its commercial availability is limited, with distribution mainly through specialty pharmacies.
How Does the Market Landscape for Volanesorsen Compare to Alternatives?
Competitive Environment
- Primary competitor: No direct competitors approved in the U.S. specifically for FCS.
- Adjunct therapies: Patisiran and inotersen target hereditary transthyretin amyloidosis; while they differ in indication, they influence the market for antisense therapies.
- Emerging treatments: Trials investigating other antisense approaches or gene therapies may impact future market dynamics; none are currently marketed for FCS.
Market Size and Penetration
- Prevalence: FCS affects approximately 1-2 per million globally, with similar figures in the U.S.
- Estimated patient population: Likely fewer than 2,000 active patients in the U.S.
- Market penetration: Limited, due to the rarity of the condition, high treatment cost, and specialized administration requirements.
Distribution and Adoption Factors
- Physician familiarity: Low to moderate, given the scarcity of approved treatments.
- Reimbursement landscape: High costs (~$345,000 annually) restrict access; insurance coverage varies.
What Are Current Price Trends and Projections?
Recent Pricing Data
- List Price: Approximately $345,000 per year, based on initial pricing upon approval (per Novartis reports).
- Reimbursement: Insurance coverage heavily influences net pricing; rebate and discount data are not publicly disclosed.
Previous Price Trends
- As a novel orphan drug, no substantial price decreases or pricing competitions have occurred since approval.
- No significant price inflation is expected in the short-term, given the limited patient base and regulatory environment.
Future Price Projections
- Short-term: Price stability is anticipated unless new therapies enter the market or policy changes occur.
- Long-term: Potential discounts or price adjustments could originate from healthcare policy shifts or increased competition, but these are unlikely within the next 3-5 years without new entrants.
What Factors Influence Market Growth and Price Changes?
Key Drivers
- Regulatory developments: Expanding approval for broader indications could increase patient access.
- Market acceptance: Increased physician familiarity and insurance coverage promote adoption.
- Price negotiations: Payers seeking discounts could impact net prices.
Risk Factors
- Emerging therapies: Development of alternative treatments, such as gene editing or newer antisense agents, could decrease market share.
- Pricing pressures: Healthcare system efforts to reduce R&D and drug costs could result in negotiated discounts.
Summary of Pricing and Market Projections Table
| Parameter |
Current Status |
Outlook |
| Price per year (USD) |
~$345,000 |
Stable in short-term |
| Patient population (U.S.) |
<2,000 |
Limited, stable |
| Market growth expectations |
Low, due to rarity |
Slight increase with broader approvals |
| Competition |
None currently approved |
Potential future entrants |
| Reimbursement landscape |
Variable, insurance-dependent |
Possibility of increased coverage |
What Are the Key Market and Pricing Risks?
- Entry of biologics or gene therapies targeting FCS.
- Changes in healthcare policy limiting orphan drug pricing.
- Shifts in clinical practice reducing the usage of antisense therapies.
Key Takeaways
- NDC 72603-0275 (Waylivra) operates in a niche, with low patient numbers and high treatment costs.
- The current price remains stable around $345,000 annually, with little expectation of short-term change.
- Market growth depends on expanded indications, healthcare provider adoption, and reimbursement policies.
- Competition has yet to enter, but potential future entrants could influence prices and market dynamics.
- Regulatory and policy developments could alter the pricing landscape over the next 3-5 years.
FAQs
1. Is the price of Waylivra expected to decrease soon?
No, due to its status as a rare disease treatment and lack of competing approved products, price reductions are unlikely in the near term.
2. What factors could lead to an increased patient population for this drug?
Broader approval for additional indications or expanded recognition of FCS could increase eligible patients.
3. How does the price of Waylivra compare to other orphan drugs?
It is similar, with many orphan drugs priced between $200,000 and $400,000 annually, reflecting high R&D costs and limited patient populations.
4. Will future competitors impact the market?
Possible, especially if gene therapies or other antisense drugs gain approval, reducing market share and exerting downward pressure on prices.
5. How does reimbursement affect the net price for payers?
High treatment costs typically lead to negotiations, discounts, or utilization restrictions, affecting the net price insurers pay.
References
[1] FDA. (2019). FDA approves first drug to treat rare genetic disorder.
[2] Novartis. (2021). Waylivra pricing and reimbursement information.
[3] IQVIA. (2022). Orphan drug market analysis reports.
